Xcout Intel
Vaxdyn competitors & alternatives
The 12 closest competitors and alternatives to Vaxdyn among biotechnology companies — ranked by similarity to what Vaxdyn actually does, not by market-cap band.
Subscribe to see Vaxdyn’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Vaxdyn
Vaxdyn is a Seville-based biotechnology spin-off founded in 2011 that develops safe and effective multi-pathogen vaccines to prevent dangerous bacterial infections.
Vaxdyn at a glance
Vaxdyn is a biotechnology company headquartered in Spain. It has raised at least $25.1M across the 2 funding rounds on record. Its most recent funding round, Series A, raised $12.1M in September 2026. Xcout tracks 4 named people at Vaxdyn, including Juanjo Infante (CEO and Chairman of the Board).
Vaxdyn leadership
- Juanjo InfanteCEO and Chairman of the Board
- Cristina ReinaDirector
- Francisco LeonDirector, Pharma Expert
- Ricardo Perdigão HenriquesDirector
Vaxdyn funding rounds
At least $25.1M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $12.1M | 5 named | |
| Series A | $13M | 6 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Recent Vaxdyn news
Top 12 Vaxdyn competitors
Ranked by semantic similarity — how close each company is to Vaxdyn by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
BioVersys AG is an award-winning, privately-owned Swiss pharmaceutical and biotech company headquartered in Basel, Switzerland, focused on the research and development of antibacterial treatments for drug-resistant bacterial infections.
Similar biotechnology company
LimmaTech Biologics is a Swiss clinical-stage biotechnology company developing vaccines against bacterial infections, including drug-resistant pathogens. Its work includes conjugate vaccine candidates for Shigella and other diseases, serving pharmaceutical partners and ultimately patients at risk of serious bacterial infections.
Similar biotechnology company
Alopexx, Inc. is a U.S. biotechnology company developing broad-spectrum anti-infective vaccines and antibody-based therapies. Its programs target PNAG, a surface polysaccharide found on many bacterial and fungal pathogens, for potential treatment or prevention of serious infections.
Similar biotechnology company
MalarVx, Inc. is a clinical-stage biopharmaceutical vaccine company located in Seattle, Washington, founded to develop innovative vaccines addressing global infectious diseases.
Biotech
Omnix Medical is a biopharmaceutical company that develops novel antibiotic agents and antimicrobial peptides to treat infections caused by drug-resistant bacteria. The company focuses on creating first-in-its-class anti-infective therapeutics, such as its lead compound OMN6, to target life-threatening bacterial strains.
Similar biotechnology company
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
Similar biotechnology company
Imaxio is a France-based biopharmaceutical company specializing in vaccines, infectiology, and genomics. The company focuses on the prevention of human leptospirosis and utilizes its proprietary antigen re-engineering technology, IMX313.
Life Sciences
Omniose is an early-stage biotechnology and life sciences company headquartered in Saint Louis, Missouri. The firm develops polysaccharide conjugate vaccines against serious bacterial threats using its proprietary technology.
Similar biotechnology company
Affinivax, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, that pioneered a novel class of multiplex vaccine technologies.
Similar biotechnology company
TXN Systems AB is a healthcare company developing an innovative antibiotic regimen targeted at treating complicated urinary tract infections caused by antibiotic-resistant bacteria.
Similar biotechnology company
Obulytix is a biotechnology startup founded in 2023 and headquartered in Ghent, Belgium, focused on advancing antimicrobial innovation and building the future of antibiotics.
Similar biotechnology company
Maxwell Biosciences, Inc. is a biotechnology company based in Austin, Texas. It develops biomimetic, peptide-inspired anti-infective drugs designed to act as a synthetic immune system.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Vaxdyn and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Vaxdynand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →